Jin et al. reported that CXCR1 and CXCR2 modified CARs significantly enhanced the persistence and migration of T cells in tumors, inducing tumor degeneration and persistent immunologic memory in preclinical models of malignancies such as glioblastoma, pancreatic and ovarian cancer (Jin et al., 2019). Here, CXCR2 is linked to neoplasm.